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Abstract
Background: A number of studies have revealed that Francisella tularensis (FT) suppresses innate immune
responses such as chemokine/cytokine production and neutrophil recruitment in the lungs following pulmonary
infection via an unidentified mechanism. The ability of FT to evade early innate immune responses could be a very
important virulence mechanism for this highly infectious bacterial pathogen.
Results: Here we describe the characterization of a galU mutant strain of FT live vaccine strain (LVS). We show that
the galU mutant was highly attenuated in a murine model of tularemia and elicited more robust innate immune
responses than the wild-type (WT) strain. These studies document that the kinetics of chemokine expression and
neutrophil recruitment into the lungs of mice challenged with the galU mutant strain are significantly more rapid
than observed with WT FT, despite the fact that there were no observed differences in TLR2 or TLR4 signaling or
replication/dissemination kinetics during the early stages of infection. We also show that the galU mutant had a
hypercytotoxic phenotype and more rapidly induced the production of IL-1b following infection either in vitro or in
vivo, indicating that attenuation of the galU mutant strain may be due (in part) to more rapid activation of the
inflammasome and/or earlier death of FT infected cells. Furthermore, we show that infection of mice with the galU
mutant strain elicits protective immunity to subsequent challenge with WT FT.
Conclusions: Disruption of the galU gene of FTLVS has little (if any) effect on in vivo infectivity, replication, or
dissemination characteristics, but is highly attenuating for virulence. The attenuated phenotype of this mutant
strain of FT appears to be related to its increased ability to induce innate inflammatory responsiveness, resulting in
more rapid recruitment of neutrophils to the lungs following pneumonic infection, and/or to its ability to kill
infected cells in an accelerated fashion. These results have identified two potentially important virulence
mechanisms used by FT. These findings could also have implications for design of a live attenuated vaccine strain
of FT because sublethal infection of mice with the galU mutant strain of FTLVS promoted development of
protective immunity to WT FTLVS.
Background
Francisella tularensis (FT) is a gram-negative intracellu-
lar bacterium that is the causal agent of tularemia. The
Francisellaceae family of bacteria has a single genus,
Francisella, which has been divided into two species: 1)
Francisella philomiragia (a muskrat pathogen) and 2)
Francisella tularensis. Francisella tularensis is further
subdivided into four subspecies: tularensis (type A),
holarctica (type B), novicida,a n dmediasiatica [1]. Of
these, only subsp. tularensis and subsp. holarctica cause
disease in humans [2]. FT tularensis is considered a
prime candidate for use as a biological weapon because it
is relatively easy to propagate and disseminate via aeroso-
lization and because of the high morbidity and mortality
associated with aerosol infection (LD50<10 CFU) [3,4].
The live vaccine strain (FT LVS), which was derived from
FT holarctica, is only moderately virulent in humans [5]
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infection in mice that is similar to the human form of
disease, the murine FT LVS infection model serves as an
appropriate animal model of human tularemic disease
[6-8].
FT is well adapted for growth and survival within host
macrophages, as evidenced by its ability to inhibit phago-
some/lysosome fusion and the respiratory burst, and to
escape from the phagosome and replicate within the
macrophage cytoplasm [9-11]. Moreover, it has been
reported that the virulence of FT depends on its ability to
escape into the host cytoplasm [10,12,13]. However, like
many other successful pathogens, the key to the patho-
genesis of FT may be in its ability to overcome, evade,
and/or suppress innate host immune responses. For
instance, FT is known to be relatively resistant to cationic
antimicrobial peptides (CAMPs), which may in part be
responsible for its ability to overcome host innate immu-
nity [14,15]. In fact, it has been shown that FT mutant
strains that are CAMP-sensitive are attenuated for viru-
lence in mice [16,17]. FT is also able to evade (in part)
innate immune detection because its lipopolysaccharide
(LPS) has unusual modifications that render it immuno-
logically inert and unable to stimulate TLR4 [17-19].
Indeed, FT novicida mutants that lacked these modifica-
tions and produced TLR4-stimulating LPS were able to
induce stronger proinflammatory cytokine production
and host innate responses resulting in rapid clearance
and an attenuated phenotype in mice [17,20]. FT also
appears to actively suppress acute inflammatory
responses at early times after infection in lungs by a
mechanism that has not yet been defined [21]. Following
pulmonary infection of mice with FT, there is an initial
l a gi nr e c r u i t m e n to fn e u t r o p h i l sa sw e l la sam i n i m a l
proinflammatory cytokine response in the first 24-48
hours following infection with FT [22,23]. This quiescent
period is typically followed by a massive neutrophil influx
and profound upregulation of cytokine production that
appears to contribute to FT pathogenesis [15,24,25]. The
ability of WT FT to delay recruitment of neutrophils
appears to be a critical virulence mechanism because FT
mutants that fail to delay influx of neutrophils are rapidly
cleared from the host and are attenuated for virulence
[17,20]. Additionally, pretreatment of mice with rIL-12
resulted in early neutrophil recruitment to lungs and
rapid immune clearance following infection with WT FT
[26]. These data suggest that the kinetics, rather than the
magnitude, of neutrophil recruitment at the site of infec-
tion are important for resolution of FT infection.
The efficacy of innate immune responses is largely
dependent on interactions between host pattern recogni-
tion receptors with cell envelope components of the invad-
ing pathogen. Because WT FT appears to utilize undefined
mechanism(s) to modulate innate immune signaling
events to gain a survival advantage in mammalian hosts,
we postulated that mutations that altered the cell envelope
structure of FT would attenuate the virulence of the bac-
terium. In this report we have tested the hypothesis that
galU is required for FT pathogenesis. The galU gene
(FTL_1357) encodes for the production of UTP-glucose-
1-phosphate uridyl transferase (or alternatively UDP-
glucose pyrophosphorylase), an enzyme that catalyzes the
formation of UDP-glucose from glucose-1-phosphate and
UTP and is known to have a key role in biosynthesis of
cell-envelope-associated carbohydrates (e.g. LPS and cap-
sule) in a variety of bacteria [27-32]. The findings reported
here revealed that disruption of the FT galU gene was
highly attenuating in vivo, and that the reduction in viru-
lence correlated with changes in the kinetics of chemokine
production and neutrophil recruitment into the lungs
following pulmonary infection. The galU mutant strain
induced more rapid production of IL-1b in vivo and
in vitro and it displayed a hypercytotoxic phenotype. We
also found that mice that survived infection with the FT
galU mutant strain developed protective immunity to sub-
sequent challenge with WT FT.
Results
Effect of galU mutation on growth and intracellular
survival of FT in vitro
The galU gene is highly conserved among the three
major subspecies of FT (100% identity between galU
genes of SchuS4 and LVS, 98.5% identity shared between
FT novicida and LVS). In gram-negative bacteria, galU is
typically part of an operon that is involved in galactose
utilization and in the production of various exopolysac-
charides [27,30,31]. The galU mutant strain characterized
here was isolated from a random transposon library of
FT LVS and was isolated as a polymyxin B hypersensitive
strain (Figure 1A). The increased sensitivity of this galU
mutant strain to cationic antimicrobials does not appear
to be due to generalized outer envelope disintegrity
because the mutant bacterium does not exhibit hypersen-
sitivity to deoxycholate (an anionic bile acid) (Figure 1A)
or the antibiotics chloramphenicol or tetracycline (data
not shown).
The galU gene product is also known to be involved (but
not required) in the catabolism of glucose and is required
for the catabolism of galactose in bacteria and yeast
[31,33,34]. Therefore, we predicted that the galU mutant
strain would display a mild growth defect in minimal med-
ium containing glucose as a sole sugar source, and would
h a v eam o r em a r k e dg r o w t hd e f e c tw h e nc u l t u r e di nm e d -
ium containing galactose as a sole source of sugar. To
determine whether the galU mutant had a galactose utili-
zation phenotype, we characterized its growth in Mueller-
Hinton broth (MHB) supplemented with either glucose or
galactose as a sole sugar source (it is important to note
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plemented with 0.1% glucose as the sole source of sugar).
As predicted, the galU mutant strain of FT displayed a
mild growth defect in MHB supplemented with glucose
and a severe growth defect in MHB supplemented with
galactose. Complementation of the galU mutation restored
WT growth kinetics in MHB supplemented with either
glucose or galactose (Figure 1B).
To determine if mutation of the galU gene resulted in
an intracellular growth defect, we evaluated the ability
of the WT and galU mutant strains of FT to grow
within murine macrophage-like cells in vitro. The repli-
cation kinetics of the galU mutant within J774 or RAW
264.7 cells were indistinguishable from those of the WT
strain (Figure 1C), indicating that mutation of the galU
gene had no effect on uptake or intracellular survival/
replication of the bacterium.
Virulence of the galU mutant in vivo
To determine whether the galU gene is important for FT
virulence, C57Bl/6J mice (5/group) were inoculated intra-
nasally with 5 × 10
4 CFU (50 × LD50) of either the galU
mutant or WT FT and then were monitored for 15 days.
Each of the mice challenged with the galU mutant
experienced transient weight loss but survived and com-
pletely cleared the infection, while all of the mice
Figure 1 Growth kinetics of the galU mutant in vitro. Growth of wild-type, galU mutant, and galU-complemented strains of FT after 48 hrs of
culture was measured by the gradient plating technique to determine their sensitivity to polymyxin-B and deoxycholate. All data points
represent the mean (
± SEM) of triplicate samples. Statistical analyses were performed via one-way ANOVA with Bonferroni post-tests. Statistically
significant differences are indicated as follows: P < 0.01 (**) (Panel A). Growth of each strain cultured in MHB supplemented with either 0.1%
glucose or 2% D-galactose (Panel B) or within macrophage-like murine cell lines (J774 or RAW264.7 at an MOI of 10, Panel C) was monitored
over a 24 hour period. All data points represent the mean (
± SEM) of triplicate samples. Each panel is representative of at least three experiments
of similar design. Statistical analyses were performed via two-way ANOVA with Bonferroni post-tests. Statistically significant differences are
indicated as follows: P < 0.01 (**) and P < 0.001 (***).
Jayakar et al. BMC Microbiology 2011, 11:179
http://www.biomedcentral.com/1471-2180/11/179
Page 3 of 16challenged with WT FT lost weight continually until they
succumbed to tularemia (Figure 2A and 2B). An addi-
tional challenge trial in which C57Bl/6 mice (4/group)
were challenged with higher numbers of the galU mutant
(up to 10
7 CFU) revealed that this mutant is highly atte-
nuated, with an LD50 that is at least 5 logs higher than
that of WT FT (Figure 2C). Moreover, trans-complemen-
tation of the galU mutation completely restored virulence
of the mutant strain (Figure 2A). These findings indicated
that FT virulence in mice is dependent on the expression
of a functional galU gene product.
To determine whether the reduced virulence of the galU
mutant was the result of defective replication and/or disse-
mination of the bacterium in vivo, we performed a kinetic
analysis of bacterial burdens following infection. C57Bl/6J
mice (16/group) were challenged with 5 × 10
4 CFU of
either the galU mutant or WT FT and then four mice
were sacrificed at each time point (24, 48, 72, and 96 h
post-infection) for bacterial burden determinations from
the lungs, livers, and spleens (Figure 3). The bacterial bur-
dens observed in the galU mutant- and WT-infected mice
were similar in each of the tissues for the first 48 h, indi-
cating that mutation of galU did not confer any significant
defects in replication or dissemination of FT in vivo.H o w -
ever, the burdens observed in the galU mutant-infected
mice were significantly lower (p < 0.01) in the spleens and
livers (p < 0.001) of infected mice at the 96 h time point.
Collectively, these results reveal that despite its normal
replication/dissemination phenotypes, the galU mutant is
more readily cleared than WT FT.
Mutation of galU alters the kinetics of innate immune
responses
To determine whether differences in innate immune
recognition of infection might be responsible for the dra-
matic difference in the outcome of disease with the galU
mutant vs. WT FT, we analyzed the kinetics of immune
cell infiltration into the lungs following infection. BALF
were collected from each mouse at the time of sacrifice
and a series of flow cytometric analyses was performed.
The numbers of macrophages, dendritic cells, and NK
cells recruited into the lungs of mice infected with the
galU mutant and WT FT were similar at each time point
(data not shown). However, higher numbers of neutro-
p h i l sw e r eo b s e r v e di nt h el u n g so fm i c ei n f e c t e dw i t h
the galU mutant at the 24- and 48-hour time points, with
peak numbers of neutrophils measured at 48 hours post-
infection (Figure 4A). In contrast, the kinetics of recruit-
ment of neutrophils into the lungs of mice infected with
WT FT was much slower (Figure 4A), peaking five days
post-infection (data not shown).
Using a Luminex multiplex kit, we also measured the
levels of a panel of cytokines/chemokines in the BALF
collected from each mouse and found that the levels of
Figure 2 Mutation of the galU gene attenuates virulence of FT.
C57BL/6 mice were infected intranasally with 5 × 10
4 CFU of WT (n
= 9), the galU mutant (n = 10), or the galU-complemented strain (n
= 5) strain of FTLVS, and their survival (Panel A) and weight (Panel
B) were monitored. Statistical analyses of survival curves was
performed using Gehan-Breslow-Wilcoxon tests and a p value of
0.005 is indicated (**). Statistical analysis of body weight retention
was performed via one-way ANOVA with a Bonferroni multiple
comparisons post-test and a p value of <0.0001 is indicated (***).
Panel C: Survival was also monitored in C57Bl/6J mice challenged
with a range of higher doses of the galU mutant (1 × 10
5-1 × 10
7
CFU; n = 4) or WT FT (5 × 10
4 CFU; n = 5). Statistical analysis of
survival curves was performed using Gehan-Breslow-Wilcoxon tests
and p values of 0.027 (*) and 0.009 (**) are indicated. Results shown
are representative of two experiments of similar design.
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granulocyte colony stimulating factor or G-CSF [36],
CXCL10/IP-10 [37], TNF-a [38], MIP-1a/CCL3 and
MIP-1b/CCL4 [39], CXCL2/MIP-2 [40], and CCL2/
MCP-1 [41] were all present at significantly higher levels
in the lungs of galU mutant-infected mice (p < 0.05) at
the 24 or 48 h time points (Figure 4B and 4C), correlat-
ing well with the peak of neutrophil recruitment at 48 h
post-infection. The levels of these same chemokines/
cytokines peaked in the lungs of WT FT-infected mice
72-96 hours post-infection (data not shown), corre-
sponding well with the peak of neutrophil recruitment
into the lungs on day five post-challenge.
It was recently reported that mutations that result in
alterations in LPS structure, making the bacterium more
likely to be recognized through TLR4 signaling, could
result in robust chemokine expression and early neutro-
phil recruitment [17,20]. To determine if the altered
kinetics of innate immune responses observed for the
galU mutant strain resulted from gross alterations to its
LPS structure, we extracted LPS from WT, galU mutant,
and wbtA mutant (O-antigen deficient) strains of FT and
performed Western blot analysis using a FT LPS-specific
mAb. No obvious alteration in LPS laddering was
observed, suggesting that mutation of galU did not result
in gross changes in synthesis of the O-antigen compo-
nent of LPS (Figure 5A). We also analyzed the ability of
L P Sd e r i v e df r o mt h egalU mutant to initiate TLR4-
mediated signaling. Using HeLa cells that stably express
either TLR2 or TLR4/MD2 that had been transfected
with a vector bearing a NFB-responsive luciferase
reporter construct, we determined that neither galU
mutant or WT FT lysates were able to stimulate TLR4
while both stimulated TLR2 to the same extent (Figure
5B), suggesting that the lipid A portion of the mutant
LPS was not altered.
To further investigate whether the galU gene resulted
in gross change(s) to the outer envelope of FT, experi-
ments were performed to measure the relative sensitivity
of galU mutant and WT FT to serum components. The
galU mutant, WT, and galU-complemented strains of FT
all displayed a similar pattern of serum sensitivity. In
contrast, an O-antigen-deficient (ΔwbtA mutant) strain
of FT was highly sensitive to serum. Interestingly, the
galU,W T ,a n dgalU-complemented strains were equally
sensitive to heat-inactivated serum, while the wbtA
mutant strain displayed no sensitivity to serum that had
been heat inactivated (Figure 5C).
IL-1 expression/activation induced by the galU mutant
vs. WT FT
Activation of the AIM2 inflammasome and production of
IL-1b and IL-18 are known to be a critical component
of the innate immune response to FT infection [42].
Figure 3 Mutation of the galU gene does not attenuate
infectivity of FT in vivo. C57BL/6 mice (4/group) were infected
intranasally with 5 × 10
4 CFU (50 × LD50 for FT LVS) of either the
WT or galU mutant strain of FT LVS. Organs were harvested at 24,
48, 72 and 96 hours p.i. and CFU/g of organ was determined for
lungs, liver, and spleen. The lower limit of detection was 20 CFU/g.
Statistical analyses were performed via two-way ANOVA with a
Bonferroni multiple comparisons post test and all significant
differences are indicated as follows: ** P < 0.01 and *** P < 0.0001.
The data shown is representative of two independent experiments
of similar design.
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Page 5 of 16Figure 4 Neutrophil recruitment and chemokine expression in the lungs following infection with the galU mutant.C 5 7 B l / 6 Jm i c e( 4 /
group) were infected intranasally with 5 × 10
4 CFU (or 50 × LD50) of either the WT or galU mutant strain of FT and BALF was collected from
individual mice at 24, 48, 72 and 96 hours post-infection. Flow cytometric analyses were performed on the cells recovered from BALF to
determine the numbers of neutrophils at each timepoint. Statistical analyses were performed via two-way ANOVA with a Bonferroni multiple
comparisons post-test and statistically significant differences (P < 0.05) are indicated (*) (Panel A). The concentrations of KC, G-CSF, MIG, and IL-
10 (Panel A) and TNF-a, MIP-1a, MIP-1b, MIP-2, and MCP-1 (Panel B) in BALF at the 24 and 48 hour time points, respectively, were determined
using a Luminex multiplex kit. Statistical analyses were performed using unpaired t tests. Statistically significant differences (*) and p values are
indicated in each panel. The data shown is representative of three independent experiments of similar design.
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Page 6 of 16Figure 5 Mutation of galU does not cause gross changes in O-antigen synthesis, serum sensitivity, or TLR signaling. Panel A: Bacterial
cell lysates (10 μg/lane) and LPS preparations of WT, galU mutant, and wbtA-mutant (O-antigen deficient) FT strains were subjected to SDS-PAGE
and Western blotting using an FT LPS-specific monoclonal antibody preparation. Panel B: HeLa-TLR4/MD-2 or HeLa-TLR2 were transiently
transfected with a ELAM-luciferase reporter construct, CMV-CD14 and CMV-b-Gal (for normalization) and stimulated for 6 hours with 2μgo r1 0 μg
of the indicated FT lysates. NF-B activation was measured via a luciferase assay. Statistical analyses were performed via one-way ANOVA and
significant differences (P < 0.0001) are indicated (***). Panel C: Bacteria were incubated for 2 h at 37°C in either PBS alone or PBS containing
either 10% or 20% fresh frozen human plasma (FFP) or 20% heat-inactivated (HI-FFP). Viable bacteria were then enumerated by dilution plating.
100% viability was defined as the number of bacteria recovered from PBS containing no serum (0% FFP), and results were plotted as the mean
(± SEM) of triplicate samples. Statistical analyses were performed via one-way ANOVA and statistically significant differences (P < 0.0001) are
indicated (***).
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infection (in vitro and in vivo) with either the galU
mutant or WT strain of FT. RNase protection analysis
revealed that IL-1b mRNA levels (as well as those of sev-
eral other cytokines) were similar in bone marrow-
derived dendritic cells (BMDC) that had been infected
for 8 h with either the galU mutant, WT, or galU-
complemented strains of FT (Figure 6A), confirming the
comparable abilities of the galU mutant and WT strains
to stimulate TLR-mediated events such as cytokine
expression. However, 24 h after infection of a macro-
phage-like cell line (THP-1) or BMDCs with the galU
mutant, the amount of IL-1b released into culture super-
natants was significantly higher (p <0 . 0 0 0 1a n dp <0 . 0 1 ,
respectively) than was observed following infection with
WT FT (Figure 6B). The galU mutant also induced accel-
erated kinetics of IL-1b protein production in vivo
(Figure 6C). Moreover, the kinetics of IL-1a protein pro-
duction is more rapid following infection with the galU
mutant strain of FT (Figure 6C).
Cytotoxicity of the galU mutant
In light of the findings that mutation of the galU gene
resulted in altered kinetics of innate signaling and earlier
production of IL-1b than was observed with WT FT, we
speculated that the galU mutant might induce death of
the host cell more rapidly than WT FT. To investigate
this possibility, we evaluated the relative abilities of the
Figure 6 galU mutant and WT FT differentially induce cleavage of pro-IL-1b to the active IL-1b form. Panel A: BMDC were infected with
WT, galU mutant, and galU-complemented strains of FT at the indicated MOI, and total RNA was extracted 8 h later and subjected to RNase
protection analysis. Panel B: IL-1b concentrations in culture supernatants from THP-1 and BMDC following infection (24 h) in vitro with either
WT, galU mutant, or galU-complemented strains of FT were determined via ELISA, and statistical analyses were performed via one-way ANOVA
with a Bonferroni multiple comparisons post-test (p values are indicated as follows: ** P < 0.01, and *** P < 0.0001). Panel C: IL-1b and IL-1a
concentrations in BALF collected from mice 48 hrs following intranasal infection with either WT or galU mutant strains of FT were determined
via multiplex cytokine analysis. Statistical analyses were performed via unpaired t tests and two-tailed p values are indicated.
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Page 8 of 16galU mutant and WT FT strains to kill their host cells
in vitro. A macrophage-like cell line (J774) was infected
with either the galU mutant or WT FT strains at an
MOI of 100 and incubated for 24 hours. LDH activity in
the culture medium was then determined as a measure
of host cell death. A significantly higher amount of LDH
activity was measured in the supernatants of J774 cells
that had been infected with the galU mutant compared
to those infected with WT FT (p < 0.0001), indicating
that the galU mutant was hyper-cytotoxic. Complemen-
tation of the galU mutation in trans partially restored
the cytotoxicity phenotype. For comparative purposes, a
wbtA mutant strain of FT was also included and was
shown to have cytotoxicity characteristics similar to
those of WT FT (Figure 7).
Immunization with the galU mutant confers immunity to
WT FT challenge
Because infection with the galU mutant elicited a robust
innate immune response and in f e c t e dm i c ew e r ea b l et o
clear the infection, we assessed the efficacy of the galU
mutant strain as a live attenuated vaccine strain. Two
months following the initial inoculation, mice that sur-
vived infection with the galU mutant, as well as a naïve
group of mice, were challenged with a large dose of WT
(50 × LD50) via the intranasal route and were monitored
for survival. The galU mutant-immunized mice experi-
enced transient weight loss following challenge, but dis-
played no other visible symptoms of tularemic disease
and survived the infection. In contrast, each of the naive
mice displayed the typical visible signs of tularemia (lack
of grooming, hunched posture, reduced motor activity,
etc.) and succumbed to WT FT infection by day 8 post-
challenge (Figure 8).
Discussion
A major focus of FT research continues to be the identifi-
cation of virulence-mechanisms used by this extremely
virulent pathogen. A number of virulence determinants
have been identified, but there remains much to discover
regarding the virulence mechanisms used by FT to survive
and cause disease within its mammalian hosts. In this
report we show that mutation of galU results in a dramatic
attenuation of FTLVS virulence that appears to be unre-
lated to any in vivo infectivity or growth defects. Although
it is known that mutation of the galU gene leaves some
other bacterial pathogens attenuated for virulence
[27,32,43,44], this is the first report examining the role of
galU in the pathogenesis of FT.
Neutrophils are a critical component of the innate
immune responses to bacterial infection, and the recruit-
ment of these cells into the lungs following pneumonic
infection typically peaks by 48-hours post-infection
[45-47]. However, it has been reported elsewhere [22,25]
and confirmed here that neutrophil recruitment follow-
ing wild type FT infection in the lungs is not detected
until approximately 72 h post-infection. Because it is
known that neutrophils are required for control of FT
infection [48], it is reasonable to speculate that the ability
of FT to delay the kinetics of neutrophil recruitment into
the lungs following pulmonary infection may be an
important virulence determinant. Interestingly, a com-
parative analysis following pulmonary infection of mice
with the galU mutant and WT strains of FT revealed that
the kinetics of neutrophil recruitment (and production of
chemokines/cytokines involved in neutrophil recruit-
ment) occurs much more rapidly following infection with
the galU mutant (peaks at 48 h post-infection). Kinetic
analyses of bacterial burdens in the lungs, spleens, and
livers of mice following infection with the galU mutant
and WT strains of FT revealed that the two strains disse-
minated and replicated at comparable rates, but the bac-
terial burdens in galU-infected animals became
significantly lower than in WT-infected animals by 72 h
post-infection. The significant difference in bacterial
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Figure 7 Mutation of the galU gene increases cytotoxicity of
FT. Murine macrophage-like cells (J774) were infected with the WT,
galU mutant, the galU-complemented, or wbtA mutant (O-antigen-
deficient) FT LVS strains at an MOI of 100. Host cell death was
determined by measuring LDH released from infected cells 24-hours
post-infection. All data points represent the mean (± SEM) of
triplicate samples and the data shown is representative of three
experiments of similar design. Statistical analyses were performed
via one-way ANOVA with a Bonferroni multiple comparisons post-
test (*** indicates a p-value of <0.0001).
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Page 9 of 16burdens observed in galU mutant- vs. WT FT-infected
mice 3-4 days post-infection may have been (at least in
part) due to differences in the kinetics of neutrophil
recruitment.
It remains unclear whether FT actively suppresses
innate immune responses during the early stages of infec-
tion, or if the delayed response is due to poor recognition
of FT through host pattern recognition receptors. It has
been well documented that FT produces an atypical LPS
that is not recognized via TLR4 [49-51] and that FT is
recognized via the TLR2 signaling pathway [52-55].
Because the galU gene has been shown to be important
for LPS production [27,31,32,43,56] in a number of other
bacterial systems, we performed a series of studies to
determine whether differences in the LPS expressed by
the FT galU mutant might contribute to its reduced viru-
lence. A western blot of both bacterial extracts and LPS
preparations revealed no obvious differences in the
O-antigen laddering between the galU mutant and WT
strains of FT, suggesting that mutation of galU did not
have any gross effects on O-antigen synthesis. Because it
has been reported elsewhere [57] and confirmed here
(wbtA mutant) that the absence of O-antigen is a major
determinant of susceptibility to complement-mediated
killing, our findings that the galU mutant displayed a
WT serum sensitivity phenotype also suggested that
O-antigen synthesis was not significantly altered by
mutation of the galU gene. This finding contrasted with
reports that galU mutant strains of P. aeruginosa and
V. cholerae displayed increased serum sensitivity [31,44].
We also observed no differences between the galU
mutant and WT strains of FT with respect to signaling
via the TLR2 and TLR4 recognition pathways. It remains
possible that mutation of galU results in minor O-
antigen compositional changes, alterations in the core
oligosaccharides, or differences in the carbohydrate mod-
ification of surface proteins of FT. Moreover, in light of
the published finding that mutations causing alterations
in the lipid A of FT novicida [17,20] are highly attenuat-
ing for virulence in vivo (possibly due to altered kinetics
of cytokine/chemokine production and neutrophil mobi-
lization), we posit that mutation of the galU gene may
have an impact on the lipid A moieties of FT. A complete
analysis of the carbohydrate components of the FT galU
mutant is needed to identify such differences.
Recent studies have revealed that the innate immune
response to FT infection is complex and involves multi-
ple signaling pathways. Others and we have previously
shown that FT elicits a powerful inflammatory response
that is primarily mediated by TLR2 and caspase-1 activa-
tion [52-55]. More recently, it has been demonstrated
that the AIM-2 inflammasome mediates caspase-1 activa-
tion and secretion of mature IL-1b and IL-18 during FT
infection [42,58,59]. We predicted that the ability of the
galU mutant strain of FT to accelerate the kinetics of
inflammatory cytokine production/neutrophil mobiliza-
tion in vivo might be due to more rapid activation of the
inflammasome. To address this hypothesis, we measured
A
B
Figure 8 Infection with the galU mutant of FT LVS elicits
protective immunity WT FT LVS. C57Bl/6J mice (n = 5) that had
survived intranasal challenge with the galU mutant FT strain and
naïve control mice (n = 5) were challenged intranasally with 5 × 10
4
CFU (50 × LD50) of WT FT LVS eight weeks following the initial
infection. The body weight (Panel A) and survival (Panel B) of mice
were monitored for survival for 30 days. Statistical analyses of
changes in body weight were performed via two-way ANOVA using
a Bonferroni multiple comparisons post-test and p-values are
indicated as follows: * P < 0.05 and *** P < 0.001. Statistical analysis
of the survival data was performed using a Gehan-Breslow-Wilcoxon
test (** indicates a p-value of 0.0043).
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BMDCs infected for 24 h in vitro and found that the
galU mutant induced higher concentrations of IL-1b
than did WT FT. However, RNase protection assays
revealed that the differences in IL-1b production by galU
mutant- vs. WT FT-infected cells were not the result of
differential transcription of the IL-1b gene and, therefore,
were likely due to more robust activation of the inflam-
masome. Our findings that production of IL-1b (as well
as IL-1a) was induced significantly earlier in the lungs of
galU mutant vs. WT FT-infected mice were also consis-
tent with the hypothesis. Moreover, we showed that
macrophage-like J774 cells infected in vitro with the galU
mutant are killed more rapidly than those infected with
WT FT and that WT cytotoxicity could be partially
restored by complementation in trans with the galU
gene. These findings were consistent with the possibility
that the galU mutant more rapidly activates the inflam-
masome that, in turn, initiates host cell death via pyrop-
tosis and limits the ability of the bacteria to replicate
[60]. Based on findings with other mutant strains that
display a hypercytolytic phenotype [61,62], it could be
speculated that such a change in the in vivo life cycle of
FT could result in significant attenuation of virulence like
that observed for the galU mutant. Overall, the findings
shown here with FTLVSΔgalU are consistent with
recently published studies showing that mutation of
either mviN (FTL_1305 [63]) or ripA (FTL_1914 [64])
results in attenuated FT strains that activate the inflam-
masome more efficiently. Additional studies designed to
delineate the signaling pathway(s) that enable early
inflammasome activation by the galU mutant strain of
FT are warranted.
Because the galU mutant was so severely attenuated for
virulence, in spite of its normal ability to replicate and dis-
seminate in vivo, and because there still is no well-defined
and efficacious vaccine for FT, we performed a vaccine
trial with the galU mutant strain. Mice that had been
infected with the galU mutant and had survived the infec-
tion were challenged intranasally two months later with a
large dose (50 × LD50) of WT FT LVS and all were found
to be immune to FT. These findings, coupled with the fact
that the galU gene is 100% conserved between the LVS
and Schu S4 strains, suggest that a galU mutant strain in
the Schu S4 background could have strong prophylactic
potential as a live attenuated vaccine strain. Studies to
characterize galU in FT SchuS4 are currently underway in
our laboratory.
Conclusions
Disruption of the galU gene of FTLVS has little if any
effect on its infectivity, replication, or dissemination in
vitro, but it resulted in highly significant virulence
attenuation. The reduced virulence of the galU mutant
appears to be related to its increased ability to induce
innate immune responses following infection. Inflamma-
tory responses and chemokine/cytokine production eli-
cited by WT FT proceeds with much slower kinetics
than typically observed for other bacterial pathogens. In
contrast, the kinetics of chemokine/cytokine expression
and neutrophil recruitment is more rapid following infec-
tion with the galU mutant strain, likely resulting in more
rapid uptake and killing of bacteria by neutrophils. These
studies also revealed that disruption of the galU gene
results in a hypercytotoxic phenotype that could be due
(at least in part) to activation of the AIM-2 inflamma-
some. The accelerated death of cells infected with the
galU mutant strain presumably interferes with the nor-
mal replicative cycle of the bacterium, resulting in the
significant difference in bacterial burdens in the liver and
spleen of mice infected with the galU mutant vs. WT
strains of FTLVS observed 4 days post-infection and con-
tributing to the reduction in FTLVSΔgalU virulence.
These findings underscore the need for studies designed
to understand the mechanisms used by WT FT to alter
the kinetics of innate immune responses following infec-
tion. A thorough comparative analysis of the outer envel-
ope of the WT and galU mutant strains of FTLVS
coupled with a more detailed analysis of the innate sig-
naling that results following infection with these two
strains of FT could lead to a better understanding of the
ability of FT to avoid detection by the innate immune
system during the early stages of infection. The findings
presented here also suggest that a galU mutant strain of
FT has high potential as a platform for development of a
live attenuated tularemia vaccine strain.
Methods
Bacteria and Culture Conditions
FTLVS was a kind gift of Dr. Karen Elkins (FDA,
Bethesda, MD). The FTLVS galU mutant strain was iden-
tified by screening a LVS transposon mutant library for
mutants exhibiting elevated susceptibility to polymyxin
B .T r a n s p o s o ni n s e r t i o ni nt ot h egalU gene was verified
by DNA sequencing and the polymyxin B hypersensitive
phenotype was verified by complementation. The results
of this screen will be described in a future publication.
FT strains were grown at 37°C in Mueller-Hinton
(DIFCO/Becton Dickinson, Sparks, MD) broth modified
with 2.5% ferric pyrophosphate, 0.1% glucose, and 10%
cysteine (MMH). The galU mutant was grown under
kanamycin selection (10 μg/mL). Complementation stu-
dies were performed as follows. The galU gene was
amplified by PCR from the LVS genome using primers:
forward primer: 5’-CTCGTGGATCCGCTAAAAT-
GAAAATAAGAAAAGC-3’ and reverse primer: 5’-
ATCGCTAATCGATAAGCTATCTATTTTGAAGG-3’.
The resulting amplicon was digested with BamHI and
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similarly digested pXB167 [65], which placed the galU
gene downstream and in the same orientation as the con-
stitutively expressed orf5 promoter. The resulting plas-
mid, pXB167-galU, was then introduced into the
indicated strains by electroporation as previously
described [15,65]. The galU-complemented strain was
grown in presence of kanamycin (10 μg/mL) and carbeni-
cillin (350 μg/mL). Bacterial stocks were made from over-
night cultures of bacteria grown to OD600 of 0.7-0.9, and
aliquots were frozen at -80°C.
Antimicrobial Susceptibility Determination
Antimicrobial susceptibility was determined by the gradi-
ent agar plate method [15,66]. The gradient agar plates
were prepared in 90 mm × 90 mm Petri plates as follows.
Thirty-five milliliters of BHI-chocolate agar (without the
test compound) was poured into the square Petri dish and
allowed to harden as a wedge by elevating one side of the
plate. After the agar solidified, 35 mL of BHI-chocolate
agar containing the test compound were added to the
leveled plate and allowed to solidify. The antibiotic gradi-
ent plates were allowed to develop for 2 h and inoculated
within 3 h after preparation. Growth was measured after
two days of incubation at 37°C. All tests were performed
in triplicate. Minimal inhibitory concentrations (MIC)
were determined as follows: MIC = distance of growth
(mm) × concentration of drug (ex. μm/mL)/90 (mm).
Mice
C57BL/6 mice were purchased from Charles River
Laboratories. Mice were age-matched and used between
8 and 16 weeks of age. Mice were housed in microisola-
tor cages with food and water available ad libitum.A l l
experimental protocols were reviewed and approved by
the University of Tennessee Health Science Center
IACUC.
Intranasal Challenge of Mice with FT
Mice were lightly anesthetized using isoflurane adminis-
tered with a Vapor Stick nebulizer. Frozen stocks of FT
were thawed anew for each experiment, diluted in phos-
phate-buffered saline (PBS), and administered intranasally
(20 μl/naris). The CFUs of FT in the inocula were verified
by dilution plating. Following challenge, all mice were
monitored daily for signs of illness (decreased mobility,
ruffled fur, hunched gait) and weight loss. Upon sacrifice,
bronchoalveolar lavage was performed and spleens, livers
and lungs were collected for bacterial burden assessment.
Bacterial Burden Determination
Spleens, livers and lungs of challenged mice were removed
aseptically and homogenized (using a tissue homogenizer)
in one milliliter of sterile PBS. To disrupt cells (releasing
FT), 0.25 mL disruption buffer (2.5% saponin, 15% BSA, in
PBS) was added with light vortexing. Appropriate dilutions
of each sample were then plated in duplicate using an
Eddy Jet spiral plater (Neutec Group Inc., Farmingdale,
NY) on MMH agar plates (supplemented with 5% calf
serum) and incubated at 37°C for 48-72 hours. Colonies
were counted using a Flash & Go automated colony coun-
ter (Neutec Group Inc.).
Cell Culture, Macrophage Infection, and Cytotoxicity
Assays
J774 and RAW264.7 cells (ATCC) were propagated in
Dulbecco’s Modified Eagle’s Medium (DMEM) contain-
ing 10% fetal bovine serum. For replication assays, cells
were seeded in 24 well tissue culture plates at a density
of 2 × 10
5 cells per well. Twenty-four-hours later, FT was
added (MOI of 10) and incubated for 2 h. Gentamicin
was then added (50μg/mL) and incubated for 1 hour to
kill extracellular bacteria. Cells were then washed two
times with DMEM and incubated in fresh culture med-
ium at 37°C. At each experimental time point, cells were
washed with PBS to remove any bacteria released during
the incubation period, lysed in PBS containing 0.1%
deoxycholate, and the number of viable bacteria released
from the cells was determined via dilution plating.
For cytotoxicity (LDH) assays, J774 cells were seeded
into a 96 well plates and allowed to adhere overnight. FT
was added to wells (MOI of 100) and the plates were cen-
trifuged (800 × g, 5 min) to facilitate contact between the
cells and bacteria. After 2 hours of co-culture with bac-
teria, the culture supernatant was aspirated and replaced
with fresh media containing gentamicin (50μg/mL) and
the plates were incubated at 37°C, 5%CO2 for 24 hrs. Cul-
ture supernatants were then analyzed for LDH release
using the CytoTox Non-Radioactive Cytotoxicity Assay
(Promega) according to the manufacturer’s protocol. The
total LDH release (100% LDH in cells) was determined by
lysis of uninfected cells. The background LDH value was
defined as the level of LDH in the supernatants collected
from intact uninfected cells. The percentage of LDH
release was calculated as follows: (Sample LDH value -
background LDH value)/(Total LDH release value - Back-
ground LDH release value) × 100.
Mouse bone marrow-derived dendritic cells (BMDC)
were generated by incubating bone marrow in RPMI
1640-10%FCS supplemented with rmGM-CSF (20 ng/mL)
(R&D Systems, Minneapolis, MN) for 8 days. This proce-
dure routinely results in 60-80% CD11c
+ cells.
Bronchoalveolar Lavage (BAL) and Flow Cytometric
Analysis
BAL was performed as described previously [45]. Briefly,
BAL was performed by intratracheal injection of 1 mL of
PBS into the lungs with immediate vacuum aspiration.
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around 800 μl. Cells were recovered from BALF by cen-
trifugation and their viability was determined by trypan
blue exclusion. Protease inhibitor cocktail (Pierce, Rock-
ford, IL) was added to the BALF immediately after recov-
ery and the BALF was frozen at -80°C till further use.
Flow cytometry was performed on isolated BAL cells
using fluorochrome conjugated antibodies specific for
CD45, CD11b, F4/80, GR1, and NK1.1 (eBioscience CA,
USA). A minimum of 50,000 events/sample was collected
on a BD Biosciences LSRII cytometer (BD Biosciences, San
Jose, CA). Expression of cell surface markers was analyzed
using DIVA software. The percentage of neutrophils was
determined using gates set on live cells and CD45 expres-
sion, and neutrophils were identified as CD11b
high /Gr1
high.
Dendritic cells and NK cells were identified as CD11b
high/
GR1
lo/F480
lo and CD45
high/NK1.1
high, respectively.
Chemokine/Cytokine Measurements from BALF
The concentrations of each of the chemokines/cytokines
from BALF were determined via multiplex analysis using
a Luminex Milliplex Analyzer (Millipore Corp., Billerica,
MA). A 32-plex Milliplex Cytokine/Chemokine Immu-
noassay (Millipore) was used according to manufacturer’s
instructions to simultaneously measure the following:
eotaxin, G-CSF, GM-CSF, IFN-g, IL-1a, IL-1b, IL-2, IL-3,
IL-4, IL-5, IL-6, IL-7, IL-9, IL-10, IL-12 (p40), IL-12
(p70), IL-13, IL-15, IL-17, IP-10, KC, LIF, LIX, MCP-1,
M-CSF, MIG, MIP-1b, MIP-1a, MIP-2, RANTES, TNFa,
and VEGF. All determinations were performed with
duplicate samples, and data analysis was performed using
Luminex xPonent and Milliplex Analyst software
packages (Millipore).
Galactose Sensitivity
FT strains were grown overnight in MHB containing 0.1%
glucose and then pelleted, washed and resuspended in
PBS. Each strain was then diluted to 5 × 10
7 CFU/mL and
inoculated in fresh MHB containing either 0.1% glucose or
2% D-galactose as the sole sugar source and incubated at
37°C for 24 hours. Optical density at 600 nm was moni-
tored hourly as a measure of growth.
LPS Isolation
Bacterial cultures in mid-logarithmic growth phase were
pelleted by centrifugation at 4000 rpm for 20 min and
then resuspended in PBS. LPS was isolated from the bac-
teria using LPS extraction kit (Intron Biotechnologies,
Boca Raton, FL) as per the manufacturer’sd i r e c t i o n s .
SDS-PAGE and Western Blotting
Bacterial cell lysates (5 μg/lane) and LPS extracts were
electrophoresed on 4-20% gradient polyacrylamide gel
and transferred to nitrocellulose membrane. The mem-
brane was then blocked with 5% BSA (in PBS+0.1%
Tween-20) and probed with an FT LVS O-antigen-spe-
cific mAb (unpublished, see below). Bound antibodies
were detected by probing with HRP-conjugated goat
anti-mouse secondary antibody (Jackson Research Labs)
and visualized by addition of Western Lightning Plus-
ECL Enhanced Chemiluminescence substrate (Perkin
Elmer, Shelton, CT).
T h eO - a n t i g e n - s p e c i f i cm A bu s e df o rt h eW e s t e r n
analysis was generated as follows: Six-week old female
C57/BL6 mice were immunized (i.p.) three times at
two-week intervals with 5 × 10
7 heat-killed FTLVS.
Three weeks later each mouse was challenged/boosted
via intraperitoneal inoculation with 10
6 live FTLVS. Six
weeks later, the FT immune mice with high titer anti-
FT IgG were boosted via intraperitoneal injection of 5 ×
10
7 heat-killed FTLVS. Spleens were removed three
days later, and splenocytes were fused with P3 × 63-
Ag8.653 plasmacytoma cells as previously described
[67]. Thirteen days after fusion, hybridoma cell superna-
tants were screened via direct ELISA for IgG reactive
with sonicated FT-antigen and whole FT bacteria. The
O-antigen-specific hybridoma was cloned via limiting
dilution and mAbs were purified from culture superna-
tants via affinity chromatography using protein G-
sepharose columns (Pierce/ThermoFisher Scientific,
Rockford, IL).
Sensitivity to Human Serum
Overnight cultures of the indicated FT strains were pel-
leted via centrifugation at 4000 rpm for 20 min and
washed once with PBS. The bacteria (1 × 10
7 CFU) were
suspended in 100 μl PBS and incubated with an equal
amount of human fresh frozen plasma (citrate was used as
the anticoagulant) at varying concentrations for 2 h at
37°C. Surviving bacteria were enumerated by dilution plat-
ing on MMH plates.
TLR4/TLR2 Signaling Luciferase Assay
HeLa-TLR4/MD2 or HeLa-TLR2 [68] were transiently
transfected in 24-well plates using Effectene reagent (Qia-
gen) with 0.4μgo fE L A M - l u c i f e r a s e ,0 . 2 μgo fp c D N A -
CD14 and 0.1μgo fC M V - b-Gal expression plasmids
(recipe for 24 wells). Forty-eight hours after transfection,
the cells were stimulated for 6 hours with FT lysates. LPS
(10 ng/mL) from E. coli strain LCD25 (List Biological,
Campbell, CA) and PAM3-Cys (1μg / m L ;I n v i v o g e n ,S a n
Diego, CA) were used as controls for TLR4 and TLR2 sig-
naling, respectively. Luciferase assays were performed
using Promega (Madison, WI) reagents according to the
manufacturer recommendations. Efficiency of transfection
was normalized by measuring b-Gal in cell lysates.
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BMDC seeded into 24-well tissue culture plates (2 ×
10
6/well) were infected with FT and then total RNA was
isolated 8 hr later using TRizol reagent (Life Technolo-
gies, Grand Island, NY). RNase protection assays were
performed with 4μg of total RNA using a BD-Pharmin-
g e n( S a nD i e g o ,C A )R i b o q u a n tk i ta n dt h em C K - 2
multi-probe template set.
Quantitation of IL-1b Production In Vitro
BMDC or THP-1 cells were seeded into 24-well tissue
culture plates (2 × 10
6/well) and infected with FT. Gen-
tamicin was added to the medium 3 hours later. IL-1b
was measured in conditioned supernatants 24 hr post-
infection using an ELISA kit (eBiosciences, San Diego,
CA).
Statistical Methodology
Statistical analyses of each figure were performed using
GraphPad Prism software (GraphPad Software, La Jolla,
CA). The specific statistical method used for each data-
set is described in the figure legends.
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